Peptide–drug conjugate-based novel molecular drug delivery system in cancer
YS Zhu, K Tang, J Lv - Trends in pharmacological sciences, 2021 - cell.com
Drug delivery systems are generally believed to comprise drugs and excipients. A peptide–
drug conjugate is a single molecule that can simultaneously play multiple roles in a drug …
drug conjugate is a single molecule that can simultaneously play multiple roles in a drug …
Pancreatic neuroendocrine neoplasms: 2020 update on pathologic and imaging findings and classification
L Khanna, SR Prasad, A Sunnapwar, S Kondapaneni… - Radiographics, 2020 - pubs.rsna.org
Pancreatic neuroendocrine neoplasms (panNENs) are heterogeneous neoplasms with
neuroendocrine differentiation that show characteristic clinical, histomorphologic, and …
neuroendocrine differentiation that show characteristic clinical, histomorphologic, and …
Design and challenges of radiopharmaceuticals
K Vermeulen, M Vandamme, G Bormans… - Seminars in nuclear …, 2019 - Elsevier
This review describes general concepts with regard to radiopharmaceuticals for diagnostic
or therapeutic applications that help to understand the specific challenges encountered …
or therapeutic applications that help to understand the specific challenges encountered …
Potent candidates for Targeted Auger Therapy: Production and radiochemical considerations
D Filosofov, E Kurakina, V Radchenko - Nuclear Medicine and Biology, 2021 - Elsevier
Abstract Targeted Auger Therapy represents great potential for the therapy of diseases
which require a high degree of selectivity on the cellular level (eg for therapy of metastatic …
which require a high degree of selectivity on the cellular level (eg for therapy of metastatic …
18F-AlF-NOTA-octreotide outperforms 68Ga-DOTATATE/NOC PET in neuroendocrine tumor patients: results from a prospective, multicenter study
E Pauwels, F Cleeren, T Tshibangu… - Journal of Nuclear …, 2023 - Soc Nuclear Med
18F-labeled somatostatin analogs (SSAs) could represent a valid alternative to the current
gold standard, 68Ga-labeled SSAs, for somatostatin receptor imaging in patients with …
gold standard, 68Ga-labeled SSAs, for somatostatin receptor imaging in patients with …
[18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients
Purpose The widespread use of gallium-68-labelled somatostatin analogue (SSA) PET, the
current standard for somatostatin receptor (SSTR) imaging, is limited by practical and …
current standard for somatostatin receptor (SSTR) imaging, is limited by practical and …
Nuclear medicine and molecular imaging advances in the 21st century
SC Vaz, F Oliveira, K Herrmann… - The British journal of …, 2020 - academic.oup.com
Currently, Nuclear Medicine has a clearly defined role in clinical practice due to its
usefulness in many medical disciplines. It provides relevant diagnostic and therapeutic …
usefulness in many medical disciplines. It provides relevant diagnostic and therapeutic …
Management of appendix neuroendocrine neoplasms: insights on the current guidelines
Appendiceal neuroendocrine neoplasms (ANENs) usually present as incidental findings at
the time of appendectomy for acute appendicitis. They are rare, accounting for only 0.5–1 …
the time of appendectomy for acute appendicitis. They are rare, accounting for only 0.5–1 …
[HTML][HTML] Challenges in the management of tumor-induced osteomalacia (TIO)
ML Brandi, GPR Clunie, P Houillier, SMJ de Beur… - Bone, 2021 - Elsevier
Abstract Tumor-induced osteomalacia (TIO), also known as oncogenic osteomalacia, is a
rare acquired paraneoplastic disease that is challenging to diagnose and treat. TIO is …
rare acquired paraneoplastic disease that is challenging to diagnose and treat. TIO is …
Nuclear medicine imaging in neuroblastoma: current status and new developments
A Samim, GAM Tytgat, G Bleeker, STM Wenker… - Journal of Personalized …, 2021 - mdpi.com
Neuroblastoma is the most common extracranial solid malignancy in children. At diagnosis,
approximately 50% of patients present with metastatic disease. These patients are at high …
approximately 50% of patients present with metastatic disease. These patients are at high …